HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial

Andrea Cartier; Ana Milinkovic; Lisa Goodall; Borja Mora-Peris; Dana Ogaz; Adrian Palfreeman; Branca Pereira; Iain Reeves; John Saunders; Ann K. Sullivan

doi:10.1111/hiv.70045

HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial

Andrea Cartier^*, Ana Milinkovic, Lisa Goodall, Borja Mora-Peris, Dana Ogaz, Adrian Palfreeman, Branca Pereira, Iain Reeves, John Saunders, Ann K. Sullivan

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: Here we describe HIV seroconversion events in participants of the PrEP Impact trial. Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline. Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100 person-years, and mainly linked to low self-reported adherence. The emergence of drug resistance in participants reporting recent oral PrEP (tenofovir disoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (where analysis results are available, 21% of participants who seroconverted during trial participation showed drug resistance). Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention intervention. Further data are needed to assess the prevalence and impact of increasing oral PrEP TDF/FTC use on HIV resistance.

Original language	English
Pages (from-to)	1300-1303
Number of pages	4
Journal	HIV Medicine
Volume	26
Issue number	8
DOIs	https://doi.org/10.1111/hiv.70045
Publication status	Published - Aug 2025

Bibliographical note

Publisher Copyright:
© 2025 British HIV Association.

Keywords

PrEP
TDF/FTC PrEP
genotypic viral resistance
prevention
resistance
seroconversion

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/hiv.70045

Cite this

@article{a3ad44d6b7fd4516935f137b2ef68273,

title = "HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial",

abstract = "Objectives: Here we describe HIV seroconversion events in participants of the PrEP Impact trial. Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline. Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100 person-years, and mainly linked to low self-reported adherence. The emergence of drug resistance in participants reporting recent oral PrEP (tenofovir disoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (where analysis results are available, 21\% of participants who seroconverted during trial participation showed drug resistance). Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention intervention. Further data are needed to assess the prevalence and impact of increasing oral PrEP TDF/FTC use on HIV resistance.",

keywords = "PrEP, TDF/FTC PrEP, genotypic viral resistance, prevention, resistance, seroconversion",

author = "Andrea Cartier and Ana Milinkovic and Lisa Goodall and Borja Mora-Peris and Dana Ogaz and Adrian Palfreeman and Branca Pereira and Iain Reeves and John Saunders and Sullivan, \{Ann K.\}",

note = "Publisher Copyright: {\textcopyright} 2025 British HIV Association.",

year = "2025",

month = aug,

doi = "10.1111/hiv.70045",

language = "English",

volume = "26",

pages = "1300--1303",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "8",

}

TY - JOUR

T1 - HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial

AU - Cartier, Andrea

AU - Milinkovic, Ana

AU - Goodall, Lisa

AU - Mora-Peris, Borja

AU - Ogaz, Dana

AU - Palfreeman, Adrian

AU - Pereira, Branca

AU - Reeves, Iain

AU - Saunders, John

AU - Sullivan, Ann K.

PY - 2025/8

Y1 - 2025/8

N2 - Objectives: Here we describe HIV seroconversion events in participants of the PrEP Impact trial. Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline. Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100 person-years, and mainly linked to low self-reported adherence. The emergence of drug resistance in participants reporting recent oral PrEP (tenofovir disoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (where analysis results are available, 21% of participants who seroconverted during trial participation showed drug resistance). Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention intervention. Further data are needed to assess the prevalence and impact of increasing oral PrEP TDF/FTC use on HIV resistance.

AB - Objectives: Here we describe HIV seroconversion events in participants of the PrEP Impact trial. Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline. Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100 person-years, and mainly linked to low self-reported adherence. The emergence of drug resistance in participants reporting recent oral PrEP (tenofovir disoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (where analysis results are available, 21% of participants who seroconverted during trial participation showed drug resistance). Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention intervention. Further data are needed to assess the prevalence and impact of increasing oral PrEP TDF/FTC use on HIV resistance.

KW - PrEP

KW - TDF/FTC PrEP

KW - genotypic viral resistance

KW - prevention

KW - resistance

KW - seroconversion

UR - https://www.scopus.com/pages/publications/105005802331

UR - https://www.mendeley.com/catalogue/62307c18-d1e9-3697-84a7-5f7d839fee09/

U2 - 10.1111/hiv.70045

DO - 10.1111/hiv.70045

M3 - Article

AN - SCOPUS:105005802331

SN - 1464-2662

VL - 26

SP - 1300

EP - 1303

JO - HIV Medicine

JF - HIV Medicine

IS - 8

ER -

HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this